In previous work, we showed the clinical significance of 16 candidate molecular biomarkers (AZGP1, BTG2, CBX2, CNTNAP2, DNALI1, LOC389033, NME5, PIP, S100A8, SCUBE2, SERPINA11, STC2, STK32B, SUSD3, UBE2C, and WHSC1L1) in invasive breast carcinoma [14,15,23]. This evidence concerns the gene NME5 and invasive breast carcinoma.